This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolf, M. Articles by Averbuch, S. Search for Related Content PubMed PubMed Citation Articles by Wolf, M. Articles by Averbuch, S.

Development of the Novel Biologically Targeted Anticancer Agent Gefitinib

Determining the Optimum Dose for Clinical Efficacy

¹ Clinical Research, AstraZeneca Pharmaceuticals, Wilmington, Delaware, and ² AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom

ABSTRACT

The emergence of novel, biologically targeted anticancer agents such as gefitinib (‘Iressa’, ZD1839) has raised the question of how the dose for later-stage clinical development and clinical use is best determined. For cytotoxic drugs, because toxic effects and antitumor activity often fall within the same dose range and are dose dependent, the clinically used dose will depend on the therapeutic window. Therefore, the maximum tolerated dose identified in Phase I trials is typically used to determine the dose level for Phase II and III trials. However, because biologically targeted agents are expected to provide clinical benefits that are not predicted by surrogate end points of toxicity to normal replicating tissue, new Phase I trials have been designed to determine the optimum biological dose for use in further studies.

A large, multifaceted Phase I program was designed to evaluate the pharmacokinetics, safety, efficacy, and targeted biological activity of a once-daily oral dose of gefitinib. The maximum tolerated dose was 700 mg/day, although doses as low as 150 mg/day provided (a) plasma concentrations sufficient for pharmacological activity, (b) evidence of targeted biological effect, and (c) antitumor activity. From these observations, two large Phase II trials (‘Iressa’ Dose Evuluation in Advanced Lung Cancer 1 and 2) evaluated 250- and 500-mg/day doses of gefitinib in patients with advanced non-small cell lung cancer (NSCLC). As predicted from the Phase I trials, doses >250 mg/day provided no additional efficacy benefit, whereas adverse effects increased in a dose-dependent manner. Consequently, the recommended dose of gefitinib in NSCLC is 250 mg/day. The early clinical trial development of gefitinib provides a model for the development of novel, noncytotoxic anticancer agents.

This article has been cited by other articles:

				Xian Zhou, Suyu Liu, E. S Kim, R. S Herbst, and J J. Lee Bayesian adaptive design for targeted therapy development in lung cancer -- a step toward personalized medicine Clinical Trials, June 1, 2008; 5(3): 181 - 193. [Abstract] [PDF]

				F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al. Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure Clin. Cancer Res., December 1, 2006; 12(23): 7180 - 7186. [Abstract] [Full Text] [PDF]

				F. Robert, G. Blumenschein, R. S. Herbst, F. V. Fossella, J. Tseng, M. N. Saleh, and M. Needle Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naive Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., December 20, 2005; 23(36): 9089 - 9096. [Abstract] [Full Text] [PDF]

				C Festuccia, P Muzi, D Millimaggi, L Biordi, G L Gravina, S Speca, A Angelucci, V Dolo, C Vicentini, and M Bologna Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines Endocr. Relat. Cancer, December 1, 2005; 12(4): 983 - 998. [Abstract] [Full Text] [PDF]

				G. Gasparini, R. Sarmiento, S. Amici, R. Longo, D. Gattuso, M. Zancan, and M. Gion Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate Ann. Onc., December 1, 2005; 16(12): 1867 - 1873. [Abstract] [Full Text] [PDF]

				N. C. Daw, W. L. Furman, C. F. Stewart, L. C. Iacono, M. Krailo, M. L. Bernstein, J. E. Dancey, R. A. Speights, S. M. Blaney, J. M. Croop, et al. Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study J. Clin. Oncol., September 1, 2005; 23(25): 6172 - 6180. [Abstract] [Full Text] [PDF]

				D. McKillop, E. A. Partridge, J. V. Kemp, M. P. Spence, J. Kendrew, S. Barnett, P. G. Wood, P. B. Giles, A. B. Patterson, F. Bichat, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor Mol. Cancer Ther., April 1, 2005; 4(4): 641 - 649. [Abstract] [Full Text] [PDF]

				J. M. Yingling and S. Glatt Impact of PK/PD Evaluation of Targeted Therapies on Early Drug Discovery and Clinical Development Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 227 - 230. [Full Text] [PDF]

				C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]